Minoxidil

Mechanism-of-action class: Potassium Channel Interactions.

• Use to regrow hair on the top of the scalp (vertex only, see pictures on side of carton)

Directions • apply one mL with dropper 2 times a day directly onto the scalp in the hair loss area • using more or more often will not improve results • continued use is necessary to increase and keep your hair regrowth, or hair loss will begin again

For external use only. For use by men only. Flammable: Keep away from fire or flame Do not use if • you are a woman • your amount of hair loss is different than that shown on the side of this carton or your hair loss is on the front of the scalp. Minoxidil topical solution 5% is not intended for frontal baldness or receding hairline. • you have no family history of hair loss • your hair loss is sudden and/or patchy • you do not know the reason for your hair loss • you are under 18 years of age. Do not use on babies and children. • your scalp is red, inflamed, infected, irritated, or painful • you use other medicines on the scalp Ask a doctor before use if you have heart disease When using this product • do not apply on other parts of the body • avoid contact with the eyes. In case of accidental contact, rinse eyes with large amounts of cool tap water. • some people have experienced changes in hair color and/or texture • it takes time to regrow hair. Results may occur at 2 months with twice a day usage. For some men, you may need to use this product for at least 4 months before you see results. • the amount of hair regrowth is different for each person. This product will not work for all men. Stop use and ask a doctor if • chest pain, rapid heartbeat, faintness, or dizziness occurs • sudden, unexplained weight gain occurs • your hands or feet swell • scalp irritation or redness occurs • unwanted facial hair growth occurs • you do not see hair regrowth in 4 months May be harmful if used when pregnant or breast-feeding. Keep out of reach of children.

• Mar 3, 1987ANDAANDA071344Watson Labs
• Mar 3, 1987ANDAANDA071345Watson Labs
• Aug 17, 1988NDANDA019501Kenvue Brands
• Nov 14, 1988ANDAANDA071826Ph Health
• Nov 14, 1988ANDAANDA071839Ph Health
• Dec 13, 1995ANDAANDA072709Sun Pharm Industries
• Nov 14, 1997NDANDA020834Kenvue Brands
• Jan 20, 2006NDANDA021812Kenvue Brands

1. 1Adverse Drug Reaction8,51219%
2. 2Drug Ineffective7,71017%
3. 3Alopecia3,7688.5%
4. 4Application Site Pruritus2,9096.6%
5. 5Off Label Use2,2475.1%
6. 6Overdose1,4453.3%
7. 7Application Site Irritation1,4013.2%
8. 8Hair Texture Abnormal1,3973.2%
9. 9Application Site Pain1,3943.2%
10. 10Headache1,3203.0%
11. 11Incorrect Dose Administered1,2892.9%
12. 12Product Use In Unapproved Indication1,1732.7%
13. 13Inappropriate Schedule Of Product Administration1,1672.6%
14. 14Wrong Technique In Product Usage Process1,1502.6%
15. 15Pruritus1,0052.3%

Recent PubMed references pinned to Minoxidil as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

• FEA-guided co-design of bubble microneedles: controlled tip separation for rapid transdermal and sublingual delivery.
  Drug delivery · 2026 · Jiang C, Yang J, Gao M, et al.
  PMID 42118678DOI 10.1080/10717544.2026.2667564
• Enhanced follicular delivery of minoxidil to human scalp skin using cetosomal formulation.
  Colloids and surfaces. B, Biointerfaces · 2026 · Jain GK, Mishra A, Garg V, et al.
  PMID 42070486DOI 10.1016/j.colsurfb.2026.115755
• Cardiovascular Complications of Minoxidil Toxicosis in Two Dogs.
  Journal of the American Animal Hospital Association · 2026 · O'Donnell AD, Rheingold CG, Stack J, et al.
  PMID 42014099DOI 10.5326/JAAHA-MS-7538
• Topical Minoxidil and Low-Dose Oral Minoxidil in Onychodystrophy: A Proposed Treatment Algorithm.
  Journal of cosmetic dermatology · 2026 · Gupta AK, Talukder M, Lipner SR, et al.
  PMID 42003048DOI 10.1111/jocd.70863
• Microneedle-Based Codelivery of Platycladus orientalis-Derived Extracellular Vesicles and Minoxidil Nanoparticles for Androgenetic Alopecia Treatment.
  ACS applied materials & interfaces · 2026 · Shang Y, Li Z, Lin J, et al.
  PMID 41922097DOI 10.1021/acsami.6c03910
• Low-dose oral minoxidil (LDOM) and topical minoxidil: consensus recommendations for managing male and female pattern hair loss in hair transplant patients using a modified Delphi process.
  Expert opinion on pharmacotherapy · 2026 · Gupta AK, Talukder M, Williams G, et al.
  PMID 41782304DOI 10.1080/14656566.2026.2642216
• Recyclable Polymerizable Deep Eutectic Solvent-Based Three-Dimensional-Printed Dissolving Microneedles with pH-Responsive Delivery of ZIF-8-Loaded Minoxidil for Hair Loss Therapy.
  ACS applied materials & interfaces · 2026 · Aminov N, Liu H, Meng D, et al.
  PMID 41779894DOI 10.1021/acsami.6c01834
• Efficacy and safety of topical 3% minoxidil for facial hair enhancement in transmen: a randomized, double-blind, placebo-controlled trial.
  The Journal of dermatological treatment · 2026 · Wattanawinitchai K, Pomsoong C, Ratanapokasatit Y, et al.
  PMID 41778417DOI 10.1080/09546634.2026.2638637

The 10 most recently updated of 106 ClinicalTrials.gov registrations naming Minoxidil as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

• Minoxidil With or Without Low-Level Red-Light Therapy for Improving Chemotherapy-Induced Alopecia in Breast Cancer Patients
  Not yet recruiting · Phase 2 · Interventional · 50 enrolled · Ohio State University Comprehensive Cancer Center
  NCT07594678updated 2026-05-19
• Efficacy & Safety of Minoxidil SL Tablets in Men With AGA
  Completed · Phase 3 · Interventional · 142 enrolled · Samson Clinical Operations Pty Ltd
  NCT06924632updated 2026-05-18
• VENEZE Peptide Factor Hair Serum Compared With Topical 2% Minoxidil for Androgenetic Alopecia
  Recruiting · Interventional · 80 enrolled · Institute of Dermatology, Thailand
  NCT07536100updated 2026-05-13
• Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia
  Recruiting · Phase 3 · Interventional · 520 enrolled · Industrial Farmacéutica Cantabria, S.A.
  NCT05888922updated 2026-05-12
• JAK2 Expression in Androgenetic Alopecia Before and After Topical Minoxidil
  Recruiting · Interventional · 25 enrolled · Kasr El Aini Hospital
  NCT07563036updated 2026-05-01
• Effect of Low-Dose Oral Minoxidil as Treatment of Permanent Chemotherapy-Induced Alopecia
  Active not recruiting · Early phase 1 · Interventional · 14 enrolled · Northwestern University
  NCT03831334updated 2026-04-30
• Comparative Study of Microneedling With Topical Minoxidil 5% ± NB-UVB in Stable Vitiligo"
  Not yet recruiting · Phase 2 · Interventional · 30 enrolled · Sohag University
  NCT07548918updated 2026-04-29
• Clinical Study of PRP in the Treatment of Androgenetic Alopecia
  Completed · Interventional · 30 enrolled · The First Affiliated Hospital of Soochow University
  NCT07551271updated 2026-04-24
• Minoxidil for Treating White Hair: A Randomized Controlled Trial
  Completed · Phase 4 · Interventional · 141 enrolled · Southern Medical University, China
  NCT06813963updated 2026-04-20
• Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia.
  Not yet recruiting · Phase 3 · Interventional · 372 enrolled · Eurofarma Laboratorios S.A.
  NCT07529977updated 2026-04-14

Frequently asked questions

How does Minoxidil work?

Mechanism-of-action class: Potassium Channel Interactions.

What is Minoxidil used for?

According to FDA labeling, Minoxidil carries indications including: Use to regrow hair on the top of the scalp (vertex only, see pictures on side of carton). This is a reference summary of labeled uses, not medical advice or a treatment recommendation.

What class of drug is Minoxidil?

Minoxidil is classified as Other dermatologicals, Pyrimidine derivatives, Arteriolar Vasodilator, Potassium Channel Interactions, Arteriolar Vasodilation, Cutaneous Arterial Vasodilation, Decreased Blood Pressure.

What are the brand names for Minoxidil?

Minoxidil is marketed under brand names including Regoxidine, Rogaine.